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THE BIOCHEMISTRY OF 
SCHIZOPHRENIA
J. R. Smythies. M.D.
For m any years there have been two schools 
of thought concerning the aetiology of Schizo­
phrenia. Som e psychiatrists have been im­
pressed by the disturbed fam ily relationships 
and early upbringing that is com m only seen 
in cases of schizophrenia and have felt that the 
condition is largely psychogenic: that is that 
anyone subjected to these malign influences 
would develop the disease. Other psychiatrists 
have felt that schizophrenia results from  a 
genetically determined metabolic disorder and 
that the disturbed behaviour results from a 
brain with specific faults in its biochemical 
mechanism.
T w o  recent studies of what happens to the 
children of schizophrenic mothers who have 
been removed from their mothers shortly after 
birth and reared in foster homes have provided 
powerful, and I believe conclusive, evidence in 
favour of the latter view. T h is work was car­
ried out by Heston in Oregon and by Rosen­
thal and K ety in Denm ark. T h e  results show­
ed that these children in foster families 
nevertheless developed schizophrenia at the 
same rate (about 12 %  —  as compared with the 
normal expectancy of 0.8% ) as do the children 
of one schizophrenic parent reared by their 
biological mother. A  control group o f adopted 
children of normal mothers reared in similar 
foster homes showed no increased incidence. 
Then the foster families in which these child­
ren actually developed schizophrenia were
compared with those in which the children 
remained normal, and no difference could be 
detected between them. Both lots appeared 
to be ordinary families. Thus what counts for 
the developm ent of schizophrenia appears to 
be the genes and not the early fam ily environ­
ment. M oreover m any of the children of a 
schizophrenic mother, who did not develop 
actual schizophrenia, were abnormal having 
various severe forms of psychopathic person­
ality. T h is would therefore account for the 
fact that m any of the relatives of schizophrenics 
have abnormal personalities and for the fact 
that many schizophrenics com e from peculiar 
families. H owever environmental influence 
also play a role in the genetic expression, which 
is of course true for any gentically determined 
condition, such as diabetes, and even for in­
fections, such as tuberculosis. In identical 
twins, if  one twin has schizophrenia, the other 
is affected in only about 40%  of cases. B ut the 
affected twin is almost always the smaller and 
weaker with signs of relatively defective intra­
uterine nourishment.
T h e  prognosis of the illness also depends, of 
course, on environmental and psychogenic 
factors. B ut the present evidence is that most 
schizophrenics are fated from birth to develop 
the condition.
If then schizophrenia is genetically determin­
ed, presumably the faulty gene or genes arc 
expressed by some faulty enzyme(s) whose
malfunction leads to disorders in the brain 
mechanisms underlying thinking, emotional 
responses and the generation of belief and 
behaviour. In search for clues as to what the 
system concerned might be people have 
studied the mode of action of drugs that can 
induce a schizophrenia-like reaction (i.e. hallu­
cinogens such as LSD ) and those that are of 
therapeutic value in the illness (i.e. the pheno- 
thiazines and butyrophenones). To take these 
in turn. The hallucinogens produce many 
different effects in different people, but some­
times they include a ‘bad trip’ which is an 
acute psychosis with many points of similarity 
with an acute schizophrenic breakdown. The 
formulae for some well-known hallucinogens 
is shown in figure 1. It will be noted that 
many are close chemical relations to the 
neurotransmitters serotonin and dopamine, the 
simplest relation being O-methylation, N- 
methylation or both.
F i g  1 .
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This relation ship led Osmond, Harley- 
Mason and Smythies to suggest in 1952 that 
schizophrenia might be associated with some 
disorder of catecholamine metabolism so that 
mescaline-like compounds were produced in 
the brain such as D M P E  (fig. 2). Although 
this compound has been shown to be a normal 
constituent of urine (possibly of dietary origin)
there is evidence that its levels are not raised 
in schizophrenics. However it is possible that 
schizophrenics may be abnormally sensitive to 
it, particularly since it has been reported that 
schizophrenics are abnormally sensitive to the 
psychotoxic properties of its close chemical 
relative 2,3,4-trimethoxy phenylethylamine (fig. 
3). This possibility can easily be tested by 
experiment.
Fig 2.
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3,4 dimethoxyphenylethylamine
Another approach to this problem derives 
from the discovery made by Pollin et al in 
1961 that some chronic schizophrenics react to 
l-methionin with an acute psychosis. This has 
now been confirmed by four groups of workers. 
In some cases the psychosis shows features of 
a toxic psychosis and in others of an acute 
schizophreniform psychosis. About 50% of 
schizophrenics react and the rest show no re­
action at all. It is not possible to predict on 
clinical grounds which patients will react and 
which will not. The dose of 1-methionine 
required is quite small (10-20 C/day) and this 
dose produces no reaction in normal people. 
Recently an unconfirmed report from Poland 
claims that methionine increases the excretion 
of dimethyltryptamine in schizophrenics but 
only in those that react to methionine. Thus 
the basis of the methionine effect may be to 
increase transmethylation processes in the brain 
since methionine is the origin of the methyl 
groups in all transmethylation reaction in the 
body. Other unconfirmed reports in this field 
are that schizophrenics do not react with a 
toxic psychosis as normal people do to the 
methionine antimetabolite M SO  (methionine 
sulphoxamine) at a dosage of 300 mg/day. 
Also that schizophrenics methionine meta­
bolism is different from normals. Methionine 
with a C 14 label on the labile methyl group was 
given to schizophrenics and normal controls 
and the rate of excretion of C 14O2 was measured.
This was much slower in the schizophrenics 
indicating an overactive transmethylating pool.
However we cannot assume that methionine 
induces its effects by some action on the trans­
methylation system, for it has other potent 
biological actions. For example 20 G  1- 
methionine a day will cause an upset in the 
uptake of all the other amino acids and it will 
also affect secondarily tryptophan metabolism. 
The problems of how it does produce its effects 
in schizophrenics can only be settled by further 
experiment.
W e can now ask how do hallucinogens 
produce their effects on brain function for that 
may give us a clue as to the site of the disorder 
in schizophrenia. Their most marked property 
is to block central serotonin mechanisms.
This has been determined both by micro­
injection techniques onto the surface of 
individual neurones and by the following 
technique. Most of the serotonin containing 
neurones in the brain locate their cell bodies 
in the raphe nuclei of the brain stem. From 
here the axons are distributed all over the rest 
of the brain. This system seems to control 
slow-wave sleep amongst other things. If re­
cordings are made from this nucleus and d- 
LSD  injected intravenously an abrupt cessation 
of firing results.
In addition -to these drugs that mimic 
schizophrenia, we now know of several classes 
that alleviate it and are used in its clinical 
treatment. This includes the phenothiazines 
(such as chlorpromazine), the butyrophenones 
(such as haloperidol) and certain diphenylbutyl- 
piperazines (such as pimozide). These have a 
very wide range of biological effects but pro­
minent amongst them is the inhibition of 
catecholamines. Pimozide, in particular, has 
potent anti-dopamine actions. This suggests 
that schizophrenia may be associated with 
excess activity in the adrenergic and particular­
ly the dopamine system, or it may not be the 
absolute level of activity in these systems that 
may be as important as their relative level or 
balance. If the serotonin system is blocked 
there may be a relating imbalance of the ad­
renergic or dopamine systems. The thera­
peutic action of the anti-psychotic drugs may 
thus depend on their ability to reduce this 
(relative) excess activity in the adrenergic 
system so that it comes back into balance with 
the serotonin system again.
Another way to treat schizophrenia would 
be to develop drugs that would so act on the 
serotonin receptor in brain that the binding
of hallucinogens (such as dimethyltryptamine) 
would be blocked but serotonin itself could 
still bind. W e are currently working on de­
veloping such a drug based on the ‘top half' of 
LSD . Figure 3 shows a compound we have 
called T H P C  (N-methyl-1,2,4,6 tetrahydro- 
pyridine carboxamide). This is a close approx­
imation to the top half of d-LSD. If it were 
to bind in the same locus as where d-LSD 
itself acts, clearly d-LSD itself could no longer 
bind, but mescaline itself, which approximates 
in shapes to the A  + B rings of d-LSD, could. 
Therefore one would predict that T H P C  would 
block the effects of d-LSD but potentiate the 
effects of mescaline. This prediction was test­
ed using a conditioned avoidance test in rats 
that enables us to measure the ‘psychotomi­
metic’ activity of a drug and was confirmed. 
T H P C  was also shown to block the effects of 
dimethyltryptamine. Clearly then T H P C  may 
be useful in the treatment of an L SD  psychosis 
and if schizophrenia is caused by a compound 
like dimethyltryptamine, T H P C  might prove
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of therapeutic benefit, whereas if the com­
pound responsible was more like mescaline, 
T H P C  should exacerbate the illness. Thus 
T H P C  can be used as a molecular probe to try 
and determine the nature of the psychotoxin 
of schizophrenia. Even if it had no effect, this 
would provide useful evidence —  i.e. that no 
compounds similar to dimethyltryptamine or 
to mescaline were involved.
Now although the bulk of recent research
in schizophrenia has been based on the trans­
m ethylation hypothesis, other lines of study 
have produced some prom ising results. It  has 
been known for years that chronic schizo­
phrenics have a peculiar odour. Recently a 
claim has been made that the substance re­
sponsible has been identified (fig. 4). T h is was 
found in the sweat of 10 / 10  schizophrenics 
and in no normal controls. It did not appear 
to be th e product o f some bacterial flora pecu­
liar to chronic hospital wards. T h e  compound 
certainly has a most characteristic and pene­
trating odour. H owever it belongs to a 
chem ical fam ily —  a branched chain unsatur­
ated fatty acid —  never before connected with 
brain function. In fact the only com pounds I 
know of related to it that have a known bio­
logical activity are the bee ovarian hormones, 
Queen Substance and Royal Jelly , but 
this may be no more than a coincidence. A t 
any event if this report is confirmed, vigorous 
efforts should be made to trace its m etabolic 
origin.
A  very large num ber of other investigations 
have been carried out in schizophrenics but 
none has achieved any very notable results. 
Som etim es positive results have been claimed 
but subsequent work has shown these to be 
artefactual or due to m alnutrition, non- specific 
stress and other similar factors. T h is very lack 
of success has had negative results. T h e  
answer to the problem of schizophrenia can 
only com e from an intensive research effort 
directed towards discovering its biochemical 
basis. Unfortunately the skilled biochem ists
and other biological scientists needed to work 
on  such a programm e are not attracted to what 
has proven over the last 50 years to be so un­
rewarding a field. T h e  bulk of biochem ical 
research in psychiatry is currently focussed on 
the biochem ical basis of depression, in the form  
of very extensive work on the biochem istry of 
cerebral amines —  their m etabolism , uptake, 
storage and release m echanisms —  which has 
already paid handsome dividends including 
N obel Prizes to two of the main workers in 
this field. In contrast the field of schizophrenia 
research is almost totally neglected both in 
Europe and North Am erica which is strange 
when one considers the enormous economic 
cost to the com m unity and the cost in human 
suffering and blighted lives that schizophrenia 
brings about. It is not com m only realized that 
about one in 12 0  people w ill develop the illness 
at some point during their lives and that slightly 
less than one-quarter of the hospital beds in 
the country are occupied by schizophrenics.
However, now that we possess at last one 
valid fact about the physiology of schizophrenia 
—  the m ethionine effect —  the im m ediate way 
ahead is clear. T h e  biochem ical basis of the 
effect m ust be determined. Is it due to altered 
transmethylation reactions, to changed patterns 
of am inoacid uptake, to disturbances in trypto­
phan metabolism or to some other factor? 
T h e  answer to this question m ay well lead to 
other research programmes that in turn may 
further our understanding of the biochemical 
basis of one of the still outstanding problems 
of medicine.
